Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

New hygienic cutlery dispenser, DIXIE SmartStock, aids in fight against germs

Flu season is in full swing, and high-traffic establishments such as foodservice facilities must take preventive measures to ensure a hygienic and safe environment for their customers. Georgia-Pacific Professional Food Services Solutions is aiding in the fight against germs with its hygienic cutlery dispenser, DIXIE® SmartStock®.

27 Oct 2009

Boston Medical Center deploys Fusionfx Immunization Management portal to manage H1N1 vaccination

Acknowledging the critical role of Centers for Disease Control and Prevention (CDC) guidelines in ensuring the safety and efficacy of H1N1 vaccinations, Carefx Corporation, a leading provider of interoperable workflow solutions to advance the quality and safety of patient care, today announced that Boston Medical Center (BMC) has deployed the Fusionfx Immunization Management portal designed to enter and track H1N1 vaccination administration history and support broad, community-wide immunization administration tracking.

27 Oct 2009

New anti-flu drugs to fight flu virus could become a reality

New anti-flu drugs could become a reality as a result of a study carried out by academics at the University of Hertfordshire.

27 Oct 2009

Centene Corporation third-quarter 2009 net earnings increases to $22.7

Centene Corporation today announced its net earnings from continuing operations for the quarter ended September 30, 2009 were $22.7 million, or $0.51 per diluted share, compared to $18.1 million, or $0.41 per diluted share in the third quarter of 2008. The results of operations for our New Jersey health plan, University Health Plans, are classified as discontinued operations.

27 Oct 2009

Vaccination rates need improvement; racial and ethnic disparities in vaccination coverage

More teenagers are being vaccinated against human papillomavirus (HPV), meningococcal meningitis and pertussis (whooping cough), though the rates are still too low, according to recently released government data and a panel of experts convened by the National Foundation for Infectious Diseases (NFID).

27 Oct 2009

Fero Industries to complete acquisition of Pyro Pharmaceuticals by November 30, 2009

Fero Industries, Inc. is pleased to provide certain disclosures relating to the ten pending patent applications of Pyro Pharmaceuticals, Inc. As previously announced, the Company has initiated the process of acquiring Pyro Pharmaceuticals, Inc. through an exchange of Pyro’s capital stock for shares of the Company’s common stock, with Fero remaining as the parent entity and Pyro as a subsidiary. The acquisition of Pyro is expected to close by November 30, 2009.

27 Oct 2009

Consumers concerned about H1N1 flu, to avoid shopping during holiday season

Nearly one in five consumers say their concern over the H1N1 flu will cause them to avoid shopping on traditionally busy retail days during the 2009 holiday season, according to a recent Morpace Omnibus Study.

27 Oct 2009

HHS releases new flu radio PSAs to promote flu prevention messages

Today, the U.S. Department of Health and Human Services (HHS) announced the availability of thirteen new 30-second flu radio public service announcements (PSA). These new radio messages feature 13 of America’s governors and Elmo from Sesame Street.

27 Oct 2009

Genomics can provide insights in understanding emerging infectious disease

This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease.

27 Oct 2009

New data from efficacy study of CIMZIA in Crohn's disease patients presented

New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.

27 Oct 2009

Rhode Island launches new system for tracking swine flu

At a press conference featuring healthcare leaders from throughout the state, Governor Donald L. Carcieri will announce that Rhode Island has launched a new system for tracking swine flu. Unprecedented in its approach, the system makes use of prescribing data provided by pharmacies throughout the state via a secure electronic link. In yet another first for the state and the nation, Rhode Island will also announce that it has now connected 100 percent of its retail pharmacies for e-prescribing.

27 Oct 2009

New Pandemic Influenza Stress Vaccine course for health-care workers

Experts know that a pandemic can increase stress-related absenteeism among health-care workers. To help prevent this, a team of Mount Sinai Hospital psychiatrists and nurses have developed The Pandemic Influenza Stress Vaccine, a computerized course for health-care workers worldwide to build their resilience during a pandemic.

27 Oct 2009

Genetic mutations cause for SIDS and SUDS

Scientists and clinicians at the Montefiore-Einstein Center for Cardiogenetics have teamed up and found that genetic mutations leading to Long QT Syndrome (LQTS) could be causing electrical malfunctioning of the heart resulting in the mysterious deaths more commonly known as Sudden Infant Death Syndrome (SIDS) and Sudden Unexplained Death Syndrome (SUDS) in people older than 12 months of age.

27 Oct 2009

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.

27 Oct 2009

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference. Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases in humans.

27 Oct 2009

New data demonstrates CREON Delayed-Release Capsules improve fat absorption in adults with EPI

Solvay Pharmaceuticals, Inc. announced that new data demonstrate that CREON®( )(pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in adults with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery.

27 Oct 2009

President Obama declares H1N1 national emergency

President Barack Obama declared the H1N1 (swine) flu outbreak a national emergency, the Wall Street Journal reports. "The declaration, which Mr. Obama signed Friday, authorizes the administration to waive or modify certain federal requirements involving Medicare, Medicaid and health-privacy rules to speed treatment," the newspaper writes (McKay/Simpson/Whalen, 10/26).

26 Oct 2009

Swine flu 'emergency' declaration could mean expedited care

President Barack Obama declared a state of emergency as the number of swine flu cases soars and vaccine production doesn't keep up with demand.

26 Oct 2009

Cel Sci completes its production facility for Multikine Phase III clinical trial

BioMedReports, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, was given an exclusive tour of CEL-SCI Corporation's, new, state-of-the-art manufacturing facility near Baltimore, MD where the potentially ground breaking cancer immunotherapy treatment, Multikine, will be manufactured to support an upcoming Phase III clinical trial.

26 Oct 2009

Anti-viral drug development programs progress successfully, reports NanoViricides

NanoViricides, Inc. (the "Company"), reports that the Company is well financed and its game changing anti-viral drug development programs are progressing successfully. As such, Management knows of no reason for the recent decline in stock price and associated volatility.

26 Oct 2009